Introduction {#s1}
============

Inter-individual variability in susceptibility to HIV-1 infection, transmission, disease progression, and response to antiviral therapy has been attributed to host variability in multiple genes [@pone.0035020-Kaur1]. CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) are co-receptors for the entry of human immunodeficiency virus type 1 (HIV-1) into target cells [@pone.0035020-OBrien1]. A natural knockout deletion of 32 bases in CCR5 gene introduces a premature stop codon resulting in truncated protein product [@pone.0035020-Liu1]. People homozygous for CCR5-Δ32 are naturally resistant to R5 HIV infection and the heterozygous state is associated with up to 2--4 years delay in disease progression [@pone.0035020-Dean1] ^,^. Recently, Allers et al reported that they have successfully cured a HIV infected patient through CCR5-Δ32/Δ32 stem cell transplantation [@pone.0035020-Htter1], [@pone.0035020-Allers1]. On the other hand, the evidence for protection from HIV-1 infection among CCR5-Δ32 heterozygotes is mixed. A meta-analysis of Despina et al suggested that perinatal infection rates are not strongly determined by the number of functional CCR5 receptors in the children [@pone.0035020-ContopoulosIoannidis1]. For adults, some studies have reported that CCR5-Δ32 heterozygotes could be protective against HIV transmission [@pone.0035020-Oh1]--[@pone.0035020-Marmor1], whereas others have not confirmed that [@pone.0035020-Tan1]--[@pone.0035020-Deng1]. Therefore, we performed a meta-analysis of the accumulated data to address this question definitively.

Materials and Methods {#s2}
=====================

Search Strategy and Study Selection {#s2a}
-----------------------------------

English database of Google Scholar (GS), PubMed and Chinese database of CNKI were searched till June 2011 using key words: CCR5-Δ32 and HIV-1. Studies satisfying the following criteria were included: case-control studies reporting the association of CCR5-Δ32 genotype with HIV-1 susceptibility, distribution of CCR5-Δ32 genotype between the cohorts was shown, not a prenatal HIV-1 infection study.

Data Extraction and Statistical Analysis {#s2b}
----------------------------------------

Two reviewers( SiJie Liu, Jie Wu) independently performed data extraction and then checked the results together. The following information was extracted from included studies: authors, year of publication, ethnicity, country, sample size, method of CCR5-Δ32 genotyping and CCR5-Δ32 genotype of cohorts.

Odds ratio (OR) and its 95% confidence intervals (CI) were used to evaluate the association of CCR5-Δ32 heterozygotes with HIV-1 susceptibility. Subgroups were identified by ethnicity, sample size and method of CCR5-Δ32 genotyping. A chi-square-based Q-test was carried out to assess heterogeneity across studies [@pone.0035020-Cochran1]. A *P* value less than 0.10 was used to denote statistical significance. Fixed effects (Mantel and Haenszel) model was employed to pool the effects of studies without heterogeneity, otherwise the random effects (Dersirmonian and Laird) model was used [@pone.0035020-Mantel1], [@pone.0035020-Dersimonian1]. Publication bias was evaluated by Egger's and Begg's test with funnel plots [@pone.0035020-Egger1], [@pone.0035020-Begg1]. Asymmetry of the funnel plot suggests publication bias. A *P* value less than 0.05 was used to denote statistical significance. One-way sensitivity analyses were performed to examine the influence of individual studies on meta-analysis's results. Data were analyzed using Stata version 10.0 (StataCorp, College Station, Tex).

Results {#s3}
=======

[Figure 1](#pone-0035020-g001){ref-type="fig"} summarized the selection process of literatures. The electronic search yielded 1232 records, after screening over titles and/or abstracts, 24 articles were selected for further review. Finally, 18 studies involving 6427 cases and 5809 controls were included in the meta-analysis. Study sample size ranged from 140 to 2605 subjects. Study characteristics of the 18 eligible studies were summarized in [Table 1](#pone-0035020-t001){ref-type="table"}. Distribution of CCR5 genotype among subjects was shown in [Table 2](#pone-0035020-t002){ref-type="table"}. Briefly, 9 studies involved Caucasian subjects [@pone.0035020-Oh1], [@pone.0035020-Papa1]--[@pone.0035020-Philpott1], [@pone.0035020-Battiloro1], [@pone.0035020-Takacova1]--[@pone.0035020-Downer1], 4 studies involved Mongoloid subjects [@pone.0035020-Tan1], [@pone.0035020-Wang1], [@pone.0035020-Tang1], [@pone.0035020-Deng1], 3 studies involved African subjects [@pone.0035020-Oh1], [@pone.0035020-Philpott1], [@pone.0035020-Downer1], 3 studies involved Latina subjects [@pone.0035020-Philpott1], [@pone.0035020-Daz1], [@pone.0035020-PazyMino1]. In addition to CCR5-Δ32 genotype, 8 studies provided the subjects' CCR2-64I genotype [@pone.0035020-Papa1], [@pone.0035020-Tan1], [@pone.0035020-Lockett1]--[@pone.0035020-Wang1], [@pone.0035020-Li1]--[@pone.0035020-Deng1], 5 studies provided the subjects' SDF-1 genotype [@pone.0035020-Tan1], [@pone.0035020-Liu2], [@pone.0035020-Wang1], [@pone.0035020-Li1], [@pone.0035020-PazyMino1]. All studies were done in subjects of mixed genders except that by Downer et al [@pone.0035020-Downer1], which only included women.

![Selection process of studies included in the meta-analysis.](pone.0035020.g001){#pone-0035020-g001}
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###### Characteristics of selected studies in the meta-analysis.

![](pone.0035020.t001){#pone-0035020-t001-1}

  Study (year)                                   Country    Genotyping method   Ethnicity   Sample size (case/control)
  --------------------------------------------- ---------- ------------------- ----------- ----------------------------
  Battiloro (2000) [@pone.0035020-Battiloro1]     Italy            PCR          Caucasian            256/806
  Deng (2004) [@pone.0035020-Deng1]               China            PCR          Mongoloid             88/119
  Diaz (2000) [@pone.0035020-Daz1]               Colombia          PCR           Latina               29/188
  Downer (2002) [@pone.0035020-Downer1]            USA          PCR-RFLP          Mixed              929/445
  Grimaldi(2002)[@pone.0035020-Grimaldi1]         Brazil           PCR            Mixed              113/549
  Li (2003) [@pone.0035020-Li1]                   China            PCR          Mongoloid             94/46
  Liu (2004) [@pone.0035020-Liu2]                  USA             PCR            Mixed              316/513
  Lockett (1999) [@pone.0035020-Lockett1]        Britain           PCR            Mixed               86/105
  Oh(2008)[@pone.0035020-Oh1]                     German           PCR          Caucasian            610/427
                                                                                 African              35/26
  Papa (2000) [@pone.0035020-Papa1]               Greece           PCR          Caucasian            138/239
  Paz-y-Mino (2005) [@pone.0035020-PazyMino1]    Ecuador           PCR           Latina               295/50
  Philpott (2003) [@pone.0035020-Philpott1]        USA          PCR-RFLP          Mixed              2047/558
  Takacova (2008) [@pone.0035020-Takacova1]      Slovakia          PCR          Caucasian            162/198
  Tan (2010) [@pone.0035020-Tan1]                 China            PCR          Mongoloid            250/237
  Tang (2010) [@pone.0035020-Tang1]               China          PCR-LDR        Mongoloid            245/223
  Trecarichi(2006)[@pone.0035020-Trecarichi1]     Italy            PCR          Caucasian            120/120
  Veloso(2010)[@pone.0035020-Veloso1]              Span            PCR          Caucasian            184/236
  Wang (2003) [@pone.0035020-Wang1]               China            PCR          Mongoloid            330/474
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###### Distribution of CCR5 genotype of included studies.

![](pone.0035020.t002){#pone-0035020-t002-2}

  Study         Ethnicity   HIV-infected   Healthy Controls   Exposed but uninfected             
  ------------ ----------- -------------- ------------------ ------------------------ ---- ----- ----
  Battiloro     Caucasian       232               24                   744             62        
  Deng          Mongoloid        88               0                    117             2         
  Diaz           Latina          28               1                    142             8    37    1
  Downer          Mixed         879               50                   422             23        
  Grimaldi        Mixed         103               10                   520             29        
  Li            Mongoloid        90               4                                         45    1
  Liu             Mixed         261               55                   354             68   69    22
  Lockett         Mixed          63               23                    38             10   40    17
  Oh            Caucasian       595              115                   352             75        
                 African         35               0                     25             1         
  Papa          Caucasian       132               6                    216             23        
  Paz-y-Mino     Latina         292               3                     50             0         
  Philpott        Mixed         1940             107                   513             45        
  Takacova      Caucasian       137               25                   164             34        
  Tan           Mongoloid       226               24                                        222   15
  Tang          Mongoloid       221               24                                        209   14
  Trecarichi    Caucasian       111               9                                         24    6
  Veloso        Caucasian       144               40                   174             26   31    5
  Wang          Mongoloid       329               1                                         473   1

CCR5 homozygotes.

CCR5-Δ32 heterozygotes.

Compared with the wild-type CCR5 homozygotes, the pooled OR for CCR5-Δ32 heterozygotes was 1.02 (95%CI, 0.88--1.19, *p* = 0.073) for healthy controls (HC) ([figure 2a](#pone-0035020-g002){ref-type="fig"}) and 0.95 (95%CI, 0.71--1.26, *p* = 0.182) for exposed uninfected (EU) controls ([figure 2b](#pone-0035020-g002){ref-type="fig"}). There was no significant between-study heterogeneity. No asymmetry is observed in the funnel plots ([figure 3a, 3b](#pone-0035020-g003){ref-type="fig"}).

![Odds ratio of HIV-1 infection of CCR5-Δ32 heterozygotes versus wild type CCR5 homozygotes.\
The area of the black square reflects the weight of each study. The diamonds represent the combined odds ratio and 95% confidence interval using the fixed effects model for (a) healthy controls (HC) and (b) exposed uninfected controls (EU).](pone.0035020.g002){#pone-0035020-g002}

![Funnel plots to detect publication bias in the meta-analysis.\
(a) Healthy controls considered; (b) exposed uninfected controls considered. The horizontal line indicates the pooled log odds ratio (OR) and guidelines to assist in visualizing the funnel are pooled at 95% pseudo confidence limits for this estimate.](pone.0035020.g003){#pone-0035020-g003}
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###### Stratified analysis of CCR5-Δ32 heterozygotes and susceptibility to HIV-1.

![](pone.0035020.t003){#pone-0035020-t003-3}

  Variable             Healthy Controls    Exposed but uninfected                      
  ------------------- ------------------- ------------------------ ------------------- -------
  Ethnicity                                                                            
  African              1.17 (0.71--1.93)           0.604                               
  Caucasian            1.06 (0.73--1.53)           0.005            1.31 (0.25--6.85)   0.029
  Latina               1.28 (0.62--2.61)           0.942                               
  Mongoloid                                                         0.63 (0.39--1.01)   0.995
  Genotyping Method                                                                    
  PCR                  0.94 (0.79--1.12)           0.239            1.04 (0.76--1.44)   0.233
  PCR-RFLP             1.32 (0.99--1.78)           0.110                               
  Sample Size                                                                          
  \>800                1.09 (0.91--1.30)           0.152                               
  \<800                0.87 (0.65--1.16)           0.144            0.81 (0.57--1.14)   0.233

*P* value of Q-test for heterogeneity test.

We also performed stratified analysis by ethnicity, sample size and method of CCR5-Δ32 genotyping. The results were summarized in [Table 3](#pone-0035020-t003){ref-type="table"}. All the results were consisted with overall analysis and no publication bias were observed.

Sensitive analysis was conducted by deleting one study at a time to examine the influence of individual data-set to the pooled ORs. All of the corresponding pooled ORs were not materially altered (Data not shown).

Discussion {#s4}
==========

Meta-analysis offers a powerful method to synthesize information of independent studies with similar intention. It has been proved that CCR5-Δ32 homozygotes are associated with near complete protection to HIV-1 infection. Moreover, published data have demonstrated that a disease-retarding effect of CCR5-Δ32 heterozygosity in HIV-1 infected individuals [@pone.0035020-Ioannidis1]. Whereas it remained unclear if a heterozygosity for CCR5-Δ32 could affect HIV-1 susceptibility. Thus we performed this meta-analysis involving 18 eligible studies with 6427 patients and 5809 controls. The study demonstrated that CCR5-Δ32 heterozygosity has little or no protective effect against HIV-1 infection among adults. This result is similar to a previous study of perinatal HIV-1 infection [@pone.0035020-ContopoulosIoannidis1]. Several factors might underlie the lack of observed association between CCR5-Δ32 heterozygosity and HIV-1 susceptibility. First, the expression of CCR5 is influenced by factors other than CCR5 genotype. Even an individual with CCR5-Δ32 heterozygosity could still express high level of CCR5 [@pone.0035020-Wu1], [@pone.0035020-deRodaHusman1]. Second, susceptibility to HIV-1 infection is affected by a combination of genes besides CCR5. The CCR5-Δ32 heterozygotes couldn't provide a full resistant to HIV-1 infection as the homozygotes. It is possible that a single Δ32 allele exerts a protective effect against HIV-1 infection only if it occurs combined with other protective factors [@pone.0035020-Hladik1].

There are a number of limitations to our study. First, although test of publication bias have generated negative results, studies solely in conference or in local journals may have been overlooked. Second, HIV-1 of X4 strain take advantage of CXCR4 as co-receptor. It has been reported that new infections in individuals are primarily established by strains that use R5 [@pone.0035020-Schuitemaker1]--[@pone.0035020-Ghaffari1]. Currently, it is remains controversial about if HIV could use CXCR4 as co-receptor in primary HIV infection [@pone.0035020-IsaacmanBeck1]. Primary infection with CXCR4-using HIV-1 strains is believed to be a rare event [@pone.0035020-Schuitemaker2]. Thus, we might believe that in most of the cases HIV-1 R5 strain cause the initial infection, rather than the X4 strain. Although we couldn't exclude the interference of X4 viruses, it is unlikely that virus of X4 strain would significantly affect the results. Third, controls of some studies were solely derived from healthy individuals. For studies concerning disease susceptibility, it'll be more proper to take samples from exposed uninfected people as controls. Fourth, susceptibility to HIV-1 is influenced by multiple factors other than CCR5, they might interfere the precision of analysis.

In conclusion, our study involving more than 12000 subjects suggested that CCR5-Δ32 heterozygosity has little effect on protecting from HIV-1 infection. Therefore, other chemokine receptors and transmission mechanisms may play a more important role.
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